


Valganciclovir-d₅ TFA

| | |
|---------------------------|---|
| Cat. No.: | HY-A0032S |
| CAS No.: | 1402924-31-5 |
| Molecular Formula: | C ₁₆ H ₁₈ D ₅ F ₃ N ₆ O ₇ |
| Molecular Weight: | 473.42 |
| Target: | CMV |
| Pathway: | Anti-infection |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|--------------------|--|
| Description | Valganciclovir-d ₅ (TFA) is the deuterium labeled Valganciclovir TFA[1]. Valganciclovir, the L-valyl ester of ganciclovir, is actually a proagent for ganciclovir. Valganciclovir is an antiviral medication used to treat cytomegalovirus infections[2][3][4]. |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.
- [2]. Sugawara M, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. *J Pharm Sci*. 2000 Jun;89(6):781-9.
- [3]. Chawla JS, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. *Transpl Infect Dis*. 2012 Jun14(3):259-67.
- [4]. O'Brien S, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. *Blood*. 2008 Feb 15111(4):1816-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA